This test is most useful if any of these apply to you.
Maybe you've been told your cholesterol is fine, but you also have diabetes, extra weight around your middle, or a parent who had a heart attack young. This test checks whether that "fine" answer is hiding too many LDL particles. LDL-P means low-density lipoprotein particle number. It counts the cholesterol-carrying particles most likely to enter artery walls, and in studies where the count and LDL cholesterol disagreed, heart risk often followed the count.
It's an emerging marker. Current U.S. cholesterol guidelines, including the 2026 ACC/AHA dyslipidemia guideline, don't recommend advanced lipoprotein testing for routine risk assessment, and when a particle-based measure is used to refine risk, that guideline names apoB as the preferred one. The lab method matters too. This version uses ion mobility, so compare your result with your own earlier ion mobility results, from the same lab if you can.
LDL particles are tiny spheres that carry cholesterol and other fats through your blood. They start out in the liver as larger, fat-rich particles and shrink into LDL as they give up their fat. Each LDL particle carries one copy of apolipoprotein B, so each particle is one unit of potential plaque exposure. The more of them you have, the more can get trapped in artery walls, and that buildup drives many heart attacks and ischemic strokes.
A standard lipid panel reports LDL-C. That is the amount of cholesterol inside these particles. How much cholesterol each particle carries varies more than twofold from one person to the next, so two people with the same LDL-C can have very different particle counts.
The evidence that LDL particles cause heart disease is unusually strong. Genetic studies, population studies, and drug trials covering more than 2 million people and more than 150,000 heart attacks, strokes, and related events agree on the main point: higher and longer exposure causes more disease, and lowering exposure lowers risk. Most of that work measured LDL cholesterol or apoB rather than ion mobility LDL-P, but those measures usually move together. Across the trial and genetic evidence, risk keeps falling as exposure falls, with no clear point where benefit stops.
Labs count LDL particles in more than one way. NMR stands for nuclear magnetic resonance. NMR spectroscopy estimates particle numbers from a magnetic signal given off by the fats inside them, so it infers the count rather than tallying particles. Ion mobility first spins the sample to remove other blood proteins, then sorts the particles by size as they drift through an electric field and counts them directly, one size band at a time.
Both methods report in the same unit, but they aren't standardized against each other and don't produce interchangeable numbers for the same sample. Cutoffs from NMR studies don't transfer directly to an ion mobility result, and switching methods or labs between tests can make your number jump with no change in your arteries. Few studies have compared ion mobility head to head with standard and other advanced lipid measures. The biology is the same whichever method you use. The scale isn't.
Across many studies, a higher particle count goes with more heart disease, and in several the count beat LDL cholesterol at predicting who would develop it. The classic discordance studies used NMR. Ion mobility has some direct outcome data too: in JUPITER and Malmo, higher ion mobility LDL particle measures predicted cardiovascular events. The ion mobility evidence base is smaller, so use the NMR studies for the direction and strength of the link, not for exact numeric cutoffs.
| Who Was Studied | What Was Compared | What They Found |
|---|---|---|
| About 3,000 adults in the Framingham Offspring Study | Particle count versus LDL cholesterol and non-HDL cholesterol for predicting future heart disease | The particle count was the stronger predictor, and a low count picked out people at lower risk better than a low LDL cholesterol did |
| About 6,800 adults from four ethnic groups in the Multi-Ethnic Study of Atherosclerosis | People whose particle count and LDL cholesterol pointed in different directions | Signs of artery disease and heart events followed the particle count, not the cholesterol |
| 284 adults at intermediate heart risk with no symptoms | Highest third versus lowest third of particle count | About 3.7 times as likely to have calcium in their heart arteries |
Sources: Cromwell et al. (Framingham Offspring Study); Otvos et al. (Multi-Ethnic Study of Atherosclerosis); Prado et al.; Mora et al. (JUPITER); Melander et al.
What this means for you: a high count is a reason to treat your heart risk as higher than your standard panel suggests, especially if a coronary calcium scan or your family history points the same way. A low count is more reassuring than a low LDL cholesterol alone, because it means fewer LDL particles are available to build plaque.
The evidence has limits. A 2009 systematic review found the link between particle count and heart disease consistent, but judged it too early to recommend routine particle testing for everyone, because the added value over standard risk factors hadn't been clearly shown across whole populations. A later analysis in the same multi-ethnic cohort found that particle measures only slightly improved how people were sorted into risk groups, didn't significantly improve overall prediction, and lost strength once standard lipids were accounted for. Across studies, LDL-P predicts risk about as well as apoB or non-HDL cholesterol, not clearly better. The count is most useful in the specific situations below.
Disagreement between the particle count and LDL cholesterol is common, and it follows a pattern. It shows up most in people with insulin resistance, metabolic syndrome, type 2 diabetes, or high triglycerides. In those conditions the liver turns out smaller particles that each carry less cholesterol, so LDL cholesterol can look normal while the count runs high. In a large study of women followed for coronary events, LDL cholesterol alone underestimated risk for some women and overestimated it for others whenever it disagreed with particle-based measures.
Statins complicate this further. They tend to lower LDL cholesterol more than they lower the particle count, so you can hit your cholesterol goal on a statin and still carry a lot of particles.
What this means for you: if you have any of those metabolic features, or you're on a statin, a normal LDL cholesterol doesn't settle the question. This is where a particle count adds the most.
An apoB test measures apolipoprotein B directly. Every plaque-forming lipoprotein particle carries one copy of this protein. That means apoB counts LDL plus the larger fat-rich remnants and Lp(a). This LDL-P result is narrower: it reports the LDL particle count by ion mobility. LDL usually makes up most of the apoB-containing particle pool, so LDL-P and apoB often agree, and a review of 25 clinical studies found that apoB and NMR-measured LDL-P carried very similar risk information, both better than LDL cholesterol.
When they disagree, apoB seems to be the better guide. In about 41,000 UK Biobank participants, risk followed apoB, and the extra risk was visible with as little as a 2% gap between the two. Lab expert groups favor apoB as the main particle test because it's cheaper, easier to get, and better standardized between labs, and the 2026 U.S. dyslipidemia guideline names apoB, not LDL-P, as the preferred particle measure. A split between them also hints at the cause: one pattern goes with insulin resistance and small LDL particles, the other with high Lp(a) or remnant particles.
What this means for you: LDL-P is most informative alongside apoB. If both are high, the message is clear. If they split, lean on apoB for risk and use the split to decide what to check next.
Your report may also show a small LDL particle count, a peak size, or a size pattern. Small, dense LDL has been tied to heart disease in many studies. In a pooled analysis of 21 studies with about 30,600 people, having high levels of small dense LDL carried about 36% more risk of coronary heart disease.
That can sound like size is the problem, but when researchers count all the particles first and then ask what size adds, the answer is very little. In about 207,000 UK Biobank participants, the number of apoB-carrying particles drove coronary risk, and particle type and size had minimal extra effect. The two findings fit together once you remember that small particles each hold less cholesterol. A person with mostly small LDL usually has more particles at the same cholesterol level, so small size works mainly as a sign of a high count, and the count is what you want to lower.
Several things can push one result away from your usual level without any change in your long-term risk.
Uncommon lab factors can affect a result. If the number is surprising or doesn't fit apoB, repeat it before acting on it.
An LDL particle count is most useful as a series. One reading shows where you are, and a series shows whether what you're doing is working while evening out the noise in any single draw. Because ion mobility cutoffs are less standardized across labs than LDL-C or apoB, your own history is the most reliable yardstick.
Get a baseline. If you start a statin, ezetimibe, a PCSK9 inhibitor, or a serious change in diet or weight, retest in about 3 months, then at least once a year. Use the same lab and the same ion mobility method every time, with the same fasting status.
Trials have measured particle counts falling with PCSK9 inhibitors, statin-based therapy, ezetimibe/simvastatin, niacin, and CETP inhibitors. Most particle trials used NMR or other methods rather than ion mobility. Exercise trials more consistently improve triglycerides and small LDL subfractions than total LDL-P, so a falling total count with training is useful personal data rather than a guaranteed trial result.
A high count calls for confirmation and context before treatment. Retest on the same method, and pair it with apoB, a standard lipid panel, and Lp(a) if you've never measured it. Lp(a) is largely inherited and usually needs only one test. Then read the combination.
If your count stays high despite treatment, if heart disease came early in your family, or if your LDL cholesterol is very high, a preventive cardiologist or lipid specialist is worth seeing. Don't wait for symptoms. Plaque builds silently for decades, and the evidence says lowering the particle burden earlier and for longer gives the largest benefit.
Evidence-backed interventions that affect your LDL-P level
LDL-P is best interpreted alongside these tests.
LDL-P is included in these pre-built panels.
See the particle-level heart risk hiding behind a normal cholesterol result.
See whether your particle count is driving heart risk even when your cholesterol number looks fine.
13 biomarkers